Abbott Laboratories (ABT) — insider trading
Health Care
Abbott Laboratories (ABT) has 11 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase among the most recent 11 (latest 2026-06-30).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Morrone Louis H. | Officer (EXECUTIVE VICE PRESIDENT) | Shares withheld for taxes / exercise cost | 269 | $92.71 | $24.9K | Form 4 |
| 2026-06-30 | Ahuja Nita | Director | Grant / award / vesting (derivative) | 347 | $90.74 | $31.5K | Form 4 |
| 2026-06-30 | Conroy Kevin T | Director | Grant / award / vesting (derivative) | 231 | $90.74 | $21.0K | Form 4 |
| 2026-06-30 | Gonzalez Patricia Paola | Director | Grant / award / vesting (derivative) | 363 | $90.74 | $32.9K | Form 4 |
| 2026-06-30 | Roman Michael F | Director | Grant / award / vesting (derivative) | 416 | $90.74 | $37.7K | Form 4 |
| 2026-06-30 | Stratton John G | Director | Grant / award / vesting (derivative) | 432 | $90.74 | $39.2K | Form 4 |
| 2026-06-27 | Cushman Elizabeth C. | Officer (EVP, GC AND SECRETARY) | Shares withheld for taxes / exercise cost | 560 | $94.12 | $52.7K | Form 4 |
| 2026-05-07 | Stratton John G | Director | Open-market purchase | 2,000 | $86.82 | $173.6K | Form 4 |
| 2026-04-28 | Moreland Mary K | Officer (EXECUTIVE VICE PRESIDENT) | Discretionary transaction | 5,314 | $94.41 | $501.7K | Form 4 |
| 2026-04-24 | Stratton John G | Director | Grant / award / vesting | 2,286 | $0.00 | $0 | Form 4 |
| 2026-04-24 | Conroy Kevin T | Director | Grant / award / vesting | 2,286 | $0.00 | $0 | Form 4 |
Ask the chat about ABT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Abbott Laboratories (ABT).
Last updated 2026-06-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.